CORT Advances Relacorilant Program With Landmark Overall Survival Win in Ovarian Cancer

Corcept Therapeutics (CORT) marked a significant milestone for its relacorilant development program when the company announced positive results from the phase III ROSELLA study on January 22. The trial evaluated relacorilant in combination with nab-paclitaxel for platinum-resistant ovarian cancer patients, successfully clearing its primary overall survival (OS) endpoint. This achievement triggered an immediate market response, with CORT shares climbing 13.7% on the news, reflecting investor optimism about the drug candidate’s clinical potential and regulatory pathway.

The ROSELLA study demonstrated compelling efficacy results. Patients receiving relacorilant plus nab-paclitaxel achieved a median overall survival of 16 months, compared to 11.9 months for those treated with nab-paclitaxel alone—translating to a 35% reduction in death risk. Beyond the survival benefit, the combination maintained a favorable safety profile consistent with nab-paclitaxel’s established tolerability pattern, meaning the clinical advantage came without imposing additional treatment burdens on patients.

Dual Clinical Endpoints Achieved Without Biomarker Restrictions

The ROSELLA trial previously met its progression-free survival (PFS) primary endpoint in April of last year, when data showed delayed disease progression compared to chemotherapy alone. The program’s success in achieving both PFS and overall survival endpoints—without requiring biomarker selection or new safety constraints—strengthens the case for relacorilant becoming a new treatment standard in platinum-resistant ovarian cancer.

Corcept’s regulatory strategy has progressed rapidly on multiple fronts. The FDA accepted the new drug application (NDA) for relacorilant combination therapy in September 2025, with an anticipated decision by July 11, 2026. Simultaneously, the company submitted a marketing authorization application to the European Medicines Agency, with European approval decisions anticipated later in 2026. These parallel regulatory pathways position CORT for potentially meaningful commercial opportunities if approvals materialize as scheduled.

Beyond the immediate combination study, Corcept is expanding relacorilant’s clinical footprint. The phase II BELLA trial is evaluating relacorilant plus nab-paclitaxel combined with Roche’s Avastin (bevacizumab)—investigating whether triple-agent therapy could offer additional patient benefit in platinum-resistant ovarian cancer. The relacorilant program is also being studied across other solid tumors including platinum-sensitive ovarian cancer, endometrial, cervical, pancreatic, and prostate cancers, suggesting multiple expansion opportunities for the compound.

FDA Regulatory Challenge Clouds Near-Term Outlook

The recent clinical success in ovarian cancer arrives amid a significant regulatory setback for CORT’s alternative indication. The FDA issued a complete response letter (CRL) regarding the NDA for relacorilant in hypercortisolism, also known as Cushing’s syndrome—a markedly different outcome from the ovarian cancer program. Despite the phase III GRACE trial meeting its primary endpoint and confirmatory evidence from the GRADIENT study, the FDA determined that additional effectiveness data was necessary before establishing a favorable benefit-risk profile for the Cushing’s syndrome indication.

This regulatory hurdle carries strategic implications for Corcept. The company currently depends substantially on Korlym—its sole marketed product for treating Cushing’s syndrome and endogenous hypercortisolism—for revenue generation. In the first nine months of 2025, Korlym generated $559.3 million in sales, representing 13.4% year-over-year growth. The delayed approval of relacorilant for Cushing’s syndrome means the company cannot immediately diversify its revenue base beyond Korlym, prolonging its commercial dependence on the established therapy.

Stock Performance Reflects Program Volatility

CORT shares demonstrate the conflicting narratives surrounding the company’s pipeline. While the January 22 advance in response to ROSELLA success was meaningful, the stock has retreated substantially from prior levels. Over the past six months, CORT has declined 40%, significantly underperforming the broader biotech industry’s 2.9% decline. This performance gap reflects market concerns about execution risks, regulatory uncertainties, and the company’s heavy reliance on Korlym’s commercial momentum.

The coming months will be critical for sentiment. Should the FDA approve relacorilant for platinum-resistant ovarian cancer by the July 2026 target date, and if European regulators follow with favorable decisions, CORT could establish a meaningful second revenue driver beyond Korlym. Conversely, any delays or unexpected regulatory concerns could further pressure the stock. For investors monitoring Corcept, the platinum-resistant ovarian cancer program now represents the primary near-term catalyst, with approval probability and peak sales estimates likely to inform valuations through the second half of 2026.